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The use of high performance anion exchange chromatography for the 
detection of counterfeit pharmaceutical products using the excipient content 
as a marker 
 
Emma Beasley, Mandeesh Suman, and Tyler Coleman 
Email: tylercoleman991@outlook.com 
Abstract 
The aim of the investigation described here was to examine the differences between 
genuine and counterfeit pharmaceutical products through the development of an 
analytical method capable of rigorously identifying the sugar-based excipients. High 
Performance Anion Exchange Chromatography, coupled to Pulsed Amperometric 
Detection (HPAEC-PAD), supported by Gas Chromatography-Mass Spectrometry 
(GC-MS), provided a method for the analysis of the carbohydrate based excipients. 
The analytical method was able to discriminate between the substitution patterns of a 
number of monosaccharides derived from commonly used excipients and these were 
compared for both genuine and counterfeit sildenafil citrate based products. The aim 
of the project was accomplished: the HPAEC-method was employed to analyse a 
counterfeit pharmaceutical ‘Herbal Viagra’. 
Keywords: High Performance Anion Exchange Chromatography; Drug Excipients; 
Carbohydrates; Sildenafil Citrate. 
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Introduction 
Millions of people use pharmaceutical products every day, they are used to cure 
ailments, to treat disease and as preventative measures against diseases. The 
Pharmaceutical Industry is one of the biggest industries in the world with a net worth 
estimated at $300-400 billion a year according to the World Health Organisation 
(WHO)1. The continued growth and success of this industry requires consumers to be 
confident about the supply of safe medicines; however, the supply of counterfeit 
pharmaceutical products is on the increase. Counterfeit medicines present 
unprecedented danger to the unknowing consumers and also hinder the growth of 
genuine products by reducing the revenues needed for their development.  
The counterfeit medicine industry is now a global problem. Whilst no current figures 
are available on the extent of the problem, the WHO estimated the sales of 
counterfeit medicines to be worth $75 billion a year worldwide in 20102. Pfizer’s 
pharmaceutical security institute define counterfeit medicines as: 
 ‘A medicine that has been deliberately and fraudulently produced and/or mislabelled 
with respect to its identity and/or source to make it appear to be a genuine product.’  
This definition includes drugs with no active ingredient, drugs with the wrong active 
ingredient, drugs with dangerous impurities and drugs that are mislabelled or sold in 
the wrong packaging 3. The WHO collected statistics on the different types of 
counterfeit pharmaceuticals as a bid to raise public awareness, the different types 
include: 
Products without active ingredients – 32.1%; 
Products with incorrect quantities of active ingredients – 20.2%; 
Products with correct quantities of active ingredients but with false packaging 
– 15.6%; 
Copies of an original product – 1%; 
Products with high levels of impurities and contaminants – 8.5%3. 
Up to 50% of the medicines available from internet sites which conceal their physical 
location are believed by the WHO to be counterfeit4. The numbers have grown 
significantly and the figures keep climbing. This is partially due to the variety of 
different distribution and retail networks used to supply medicines to patients in 
different parts of the world and the large price difference between branded, generic 
and counterfeit products. Unfortunately, counterfeit drugs are often very difficult to 
distinguish from their genuine equivalents and have been found within reputable 
supply chains: in the UK counterfeit pharmaceuticals have been sold in bulk to 
unwitting suppliers for use in hospitals and pharmacies. A bulk amount of fake drugs 
entered the NHS supply chain in 2007, whilst a large number were seized when the 
error was realised, 25,000 had been distributed to pharmacies and then patients. Of 
that amount, only 7,000 were ever recovered during a recall of the suspected fakes5. 
This example provides evidence that counterfeit medications and pharmaceutical 
products aren’t just simply a case of buying from dubious people or websites, but 
involves organised criminal activity.  
A wide variety of methods have been used for the detection of counterfeit 
pharmaceutical products ranging from basic to advanced and specialised techniques; 
one common attribute many methods share is the detection of the active 
pharmaceutical ingredient, also known as API6. Thin layer chromatography is a 
cheap and specific analytical method that is routinely used to detect counterfeit 
APIs7. The technique is advantageous because it is cheap and simple to run as a 
test, but disadvantages are that reference standards are needed to identify 
unknowns and the process doesn’t quantify the amount of API present. 
More advanced techniques that require specific instrumentation can also be applied. 
The use of high performance liquid chromatography (HPLC)8 and mass spectrometry 
(MS)9 are commonly used instrumental setups for the analysis and comparison of 
analytes, including pharmaceutical products. In an early publication (2004), both 
HPLC and MS were used in the discovery of counterfeit Viagra. According to the 
report published by US Drug Enforcement Agency in their Microgram Bulletin10, the 
active ingredient of Viagra, sildenafil citrate, was not found in a counterfeit product 
but had been replaced by an amphetamine.  
One problem with identifying and detecting the API is that its detection does not 
indicate if it was manufactured appropriately: the material can still be counterfeit 
material and the API could have been manufactured outside of the quality control 
systems and approval regulations (FDA/MHRA) required for licensed medication. 
Alternatively, the product may have been rebranded e.g. a generic product being 
passed off as a more expensive branded product.  
The purpose of this paper is to suggest an alternative method for the detection of 
counterfeit pharmaceutical products, one which involves the analysis of excipients. 
Drug excipients are the pharmacologically inactive ingredients that are added to 
drugs and which often make up the majority of the weight of any dose. The API of a 
drug is what dictates the mode of action of a drug, for example, a correction of 
erectile dysfunction. The excipient counterparts are added to influence (normally to 
enhance) the therapeutic efficacy of the API e.g. to encourage the formulated product 
to disintegrate and release the active ingredient at a specific point in the body, for 
example in response to a pH change trigger. The excipients are added during the 
manufacturing process, some are added so that the API survives the manufacturing 
process without degradation. Table 1 lists the most common excipient types 
alongside their usage.  
A large number of carbohydrates and carbohydrate based derivatives are used as 
drug excipients. The advantages of using carbohydrates as excipients are that they 
are cheap and plentiful. They can be sourced from a combination of natural and 
synthetic origins. They are easy to make and easy to work with as most are stable 
solids. They provide both chemical and physical properties to a formulation with 
minimal interference to the API, but most importantly, minimal interference to the 
safety of the end user. It is the many unique properties of monosaccharides, 
disaccharides and polysaccharides that provide drug excipients with their varied and 
desired attributes.  
To date, there are only limited reports11 of using excipients as markers for 
determining the authenticity of medicines and none of these use high performance 
anion exchange chromatography (HPAEC). The work described here seeks to 
address this gap in knowledge and seeks to determine if analysis of excipient 
carbohydrates by HPAEC can be used to discriminate between genuine and 
counterfeit medicines.  
 Excipient 
Class 
Ingredient  Use 
Binders Cellulose 
Hydroxypropyl cellulose 
Lactose 
Provides mechanical strength and 
binds tablet together 
Coatings Hydroxypropyl 
methylcellulose 
Provides protection against 
environmental factors. Provides 
smooth surface which produces 
less friction when swallowed. 
Controlled 
release 
 agents 
Hydroxypropyl 
methylcellulose 
Prevents breakdown of tablet until 
it has reached a specific 
destination e.g. digestive tract. 
Diluents Lactose 
Microcrystalline cellulose 
 
 
Acts as a bulking agent to make 
tablet more manageable. 
Disintegrants Corscarmellose Allows the tablet to break-up 
rapidly when exposed to moisture. 
Glidants Starch 
Cellulose 
Improves flow-ability during tablet 
manufacture 
Lubricants  Ensures tablet remains intact 
during manufacture 
Table 1: List of different types of excipients, the role they play in a formulated product 
and the carbohydrates which are used to fulfil these objectives. 
 
In order to asses if the analysis of carbohydrate excipients can be used to determine 
the origin and potential source of formulation of a counterfeit product, a drug was 
chosen which is a prescribed medication (available only via prescription within the 
UK) and also where there is a ready alternative but illicit supply (through web-sites). 
The drug chosen was sildenafil citrate which is sold as a ‘Branded Medicine’ under 
the trade name of Viagra and which is manufactured and distributed by Pfizer. 
Medicines incorporating sildenafil citrate are also available from a range of generic 
manufacturers under a variety of different trade names. Unfortunately, it is also 
widely available as a counterfeit pharmaceutical product 12.  
The legitimate branded and generic formulations of sildenafil citrate contain a variety 
of carbohydrate based excipients including: hydroxypropyl methylcellulose, cellulose, 
lactose, carboxymethyl cellulose and croscarmellose (cross-linked carboxymethyl 
cellulose). Lactose (Figure 1) is the major carbohydrate constituent of milk and is a 
disaccharide generated through the condensation of the monosaccharides galactose 
(Figure 2) and glucose (Figure 3). The most common reason for adding lactose to 
tablets is as a binder and diluent. Cellulose (Figure 4 R=OH) is a polysaccharide 
which is composed entirely of anhydroglucose units and is used for a combination of 
its ability to act as a diluent, glidant, disintegrant and for its adsorbent properties. 
Carboxymethyl cellulose (Figure 4 R = H or CH2CO2H) and hydroxypropyl 
methylcelluloses (Figure 4 R= H or Me, HOPr, MeOPr) are, as their names suggest, 
derivatives of cellulose manufactured by alkylation of the anhydroglucose units. In 
tablet formulations, one of the main reasons for adding carboxymethyl cellulose 
(CMC) is as a disintegrant. Hydroxypropyl methylcellulose (HPMC) has a more 
specific use and is frequently employed as a coating agent and, as such, HPMC is 
often present at the surface of a tablet where it influences the rate of release of the 
active ingredient. Finally, croscarmellose is cross-linked carboxymethyl cellulose 
(XCMC) and is used as a ‘super-disintegrant’. 
 
  
Figure 1. Structure of lactose 
 
 
 
Figure 2. Structure of galactose 
 
 
Figure 3. Structure of glucose 
 
 
 
Figure 4 Structure of cellulose 
 
The presence of a variety of different carbohydrates in formulated tablets make them 
ideal candidates for use in an analytical investigation of their authenticity, with the 
variation in the structures providing a potential finger-print that can be used to 
determine the origin of materials.  
A number of robust and validated methods have been devised for the analysis of 
monosaccharides and polysaccharides. The methods most frequently employed 
include ‘monomer’ analysis13 and ‘linkage’ analysis14. A key step in both procedures 
is the heating of the carbohydrate component with aqueous acid, the process 
depolymerises any polysaccharides and oligosaccharides to give either 
monosaccharides or substituted monosaccharides. Application of acid hydrolysis to 
the carbohydrate based excipients generates a mixture of monosaccharides from 
lactose and cellulose and substituted monosaccharides from HPMC, CMC and 
XCMC.  
Experimental 
Materials and Sample Preparation 
Materials 
Unless otherwise stated, general laboratory chemicals were purchased from Aldrich 
(Poole, UK) and were of analytical grade. Cellulose (Avicel) hydroxypropyl 
methylcellulose, carboxymethyl cellulose and croscarmellose standards were 
supplied by (Colorcon Ltd. Kent, UK).  
Samples of sildenafil citrate were obtained through prescription from a Pharmacy 
(West Yorkshire, UK). ‘Herbal Sildenafil Citrate’ was purchased from a web-based (E-
bay) supplier of herbal medicines. For the first set of analyses, tablets (50 mg) were 
crushed whole in a mortar and pestle. In an additional set of experiments, for those 
tablets where a blue-coating was visible, the tablet coating was carefully removed 
using a scalpel and the contents (3 mg) of both the coating and the tablet core were 
analysed separately. 
 
Acid Hydrolysis 
An aqueous solution of trifluoroacetic acid (2 cm3; 2 mol.dm-3) was added to the 
tablet sample (3.0 mg) in a pressure tube and the tube sealed. The reaction mixture 
was heated at 120 oC for 2 h. After 2 h, the samples were cooled to room 
temperature and the cap of the pressure tube was removed. The solution was 
evaporated to dryness under a constant stream of nitrogen at 65 oC to give 
monomers which were used directly (HPAEC-PAD analysis- see below) or were 
converted into their alditol acetates (GC-MS analysis-see below). 
Preparation of Alditol Acetates. 
The hydrolysed products (3.0 mg) were dissolved in ultra pure water (1.5 cm3) in a 
pressure tube and sodium borohydride (10 mg) was added. The pressure tube was 
then sealed and heated at 40 oC for 2 h. After 2 h, the sample was cooled to room 
temperature and the solution was evaporated to dryness under a constant stream of 
nitrogen at 65 oC. Once the contents of the flask had evaporated, glacial acetic acid 
(1 cm3) was added and the solution was left for 5 mins before evaporating to dryness 
under a constant stream of nitrogen at 65 oC. Once dry, methanol (1 cm3) was 
added and the solvent was removed by forced evaporation under a stream of 
nitrogen; this process was repeated a further two times. Finally, a crude mixture of 
sugar alditols was recovered which was used directly in the next step. 
Pyridine (2 cm3) and acetic anhydride (2 cm3) were added to the mixture of sugar 
alditols in a pressure tube, this was sealed then heated at 100 oC for 2 h. After 2 h, 
the tube and its contents were cooled to room temperature and the solution 
evaporated to dryness under a constant stream of nitrogen at 40 oC to give a crude 
mixture of sugar alditol acetates. The dried alditol acetates were suspended in ultra 
pure water (5 cm3) and the analytes extracted with chloroform (3 x 5 cm3). The 
combined organic layer was washed with water (2 cm3) and was dried through the 
addition of anhydrous sodium sulphate. Once dry, the solution was filtered and the 
liquid evaporated under a stream of nitrogen. The resulting solid was dissolved in 
acetone (2 cm3) before being analysed using GC-MS. 
Analytical Methods 
High Performance Anion Exchange Chromatography with Pulsed Amperometric 
Detection (HPAEC-PAD)  
HPAEC was performed on a Dionex ICS-3000 HPAEC system (Thermo UK Ltd. 
Hemel Hempstead, UK) operating in isocratic mode and using a PAD detector and 
employing a quadruple potential waveform. Anion separation was performed on a 
Dionex CarboPac PA20 column (6 µm particle size, 250 mm length, 3 mm internal 
diameter and ≤ 10 Å pore size) and a CarboPac PA20 guard column (3 x 150 mm). 
Unless otherwise stated, analytes were eluted with a NaOH (4mM-10 mM) isocratic 
mobile phase at a flow rate of either 0.3 ml.min-1 or 0.45 ml.min-1 and following 
every fifth analysis, the column was regenerated by eluting the column with NaOH 
(200 mM) for 15 mins followed by equilibration with the mobile phase for 15 mins 
before the next injection. 
Gas Chromatography-Mass Spectrometry (GC-MS).  
 
GC-MS analysis was performed on an Agilent 7890A GC (Agilent Technologies UK 
Ltd. Cheshire, UK) equipped with an Agilent 5975B inert XL EI/CI MSD (Agilent 
Technologies UK Ltd.). Samples, 1 µl split-injection (ratio 10:1) were eluted from an 
Agilent HP5-MS (30 m x 250 µm-id, 0.25 µm) column (Agilent Technologies UK Ltd.) 
eluting with helium (1 mL.min-1) and employing electron impact ionisation (70 kev). 
The GC-Oven was originally set at 160 °C for 1 min, before rising to 240°C (+3 
°C.min-1), and finally being held at 240 °C for 5 mins before returning to 160 oC; the 
total run time was 33 mins. 
 
Results  
 
Determination of Retention Times of Standards 
 
Analysis of Standards by HPAEC  
 
HPAEC analysis of a series of standards was performed to determine the retention 
times of the unsubstituted monosaccharides and to establish the substitution patterns 
for the cellulose derivatives. The HPAEC-PAD results for lactose and cellulose 
confirmed the retention times for glucose as 6.5 min (NaOH 6mM) and galactose as 
6.0 min (NaOH 6mM) respectively. Under the analytical conditions employed in the 
present study, when croscarmellose and carboxymethyl cellulose were hydrolysed 
and analysed by HPAEC, a single peak eluting at the same retention time as that of 
glucose was observed. When HPMC was analysed a complex chromatograph was 
observed (Figure 5 NaOH 6 mM): six main peaks were visible with the final peak 
having the same retention time as that of the standard glucose. 
 
Analysis of Standards by GC-MS  
 
GC-MS analysis of the standards gave similar results to the HPAEC analysis. The 
retention times for per-O-acetylglucitol and per-O-acetylgalactitol (derived from 
glucose and galactose respectively) were 12.9 and 13.3 mins. Again, carboxymethyl 
cellulose and croscarmellose both gave a single peak which eluted at the same time 
as per-O-acetylglucitol. Analysis of HPMC by GC-MS gave a complex pattern of 
peaks; seven tall well resolved peaks were observed and a large number of smaller 
peaks were also visible (Figure 6). As was the case for the HPAEC analysis, the final 
tall peak in the HMPC trace co-eluted with that of the per-O-acetylglucitol. 
 
 Figure 5. HPAEC-PAD chromatograph for a hydrolysed HPMC standard run with an 
isocratic mobile phase (NaOH 6 mM) 
 
Figure 6. GC-MS chromatograph for a mixture of substituted alditol acetates derived 
from a HPMC standard 
Analysis of the sildenafil citrate tablets  
 
HPAEC-PAD & GC-MS Analysis of the combined coat and core of a sildenafil citrate 
tablet from a generic product  
 
HPAEC-PAD and GC-MS traces generated from the analysis of the combined coat 
and core of a representative generic tablet gave two major peaks (Figure 7 (HPAEC 
– NaOH 4mM) Figure 8 (GC-MS)) corresponding to the free monomers galactose 
and glucose in the HPAEC & the corresponding per-O-acetyl-alditols in the GC-MS.  
 
 
Figure 7. HPAEC-PAD chromatograph for a hydrolysed sample of a generic sildenafil 
citrate sample including both core and coat run with an isocratic mobile phase (NaOH 
4 mM) 
 Figure 8. GC-MS chromatograph for a mixture of substituted alditol acetates derived 
from a generic sildenafil citrate sample including both core and coat 
 
HPAEC-PAD & GC-MS Analysis of the film-coat of sildenafil citrate tablets from a 
generic manufacturer and the branded product from Pfizer  
 
HPAEC-PAD analysis of the coats from the branded and generic sildenafil citrate 
tablets produced different chromatographs. The branded (Pfizer) tablet gave a 
complex HPAEC-trace (Figure 9 – NaOH 5 mM) which included two major peaks with 
retention times similar to those of glucose and galactose at the end of the trace and a 
number of medium-sized over-lapping peaks eluting in front of the unsubstituted 
monosaccharides, which are reminiscent of those observed in the HPMC samples. A 
similar pattern was observed in the GC-MS trace (Figure 10). 
 
 Figure 9. HPAEC-PAD chromatogram for a hydrolysed sample of the film coating of a 
branded sildenafil citrate sample with an isocratic mobile phase (NaOH 5 mM) 
 Figure 10. GC-MS chromatograph for a mixture of substituted alditol acetates derived 
from a sample of the film coating of a branded sildenafil citrate sample.  
 
For the generic formulation the HPAEC trace of the coat has a similar overall profile: 
two major peaks corresponding to galactose and glucose appear at the end of the 
trace and these follow a number of much smaller peaks which, again, are reminiscent 
of those observed in the HPMC samples (Figure 11); the same is true for the GC-MS 
profile (Figure 12).  
 
 Figure 11. HPAEC-PAD chromatographfor a hydrolysed sample the film coating of a 
generic sildenafil citrate sample with an isocratic mobile phase (NaOH 5 mM) 
 Figure 12. GC-MS chromatograph for a mixture of substituted alditol acetates derived 
from a sample of the film coating of a generic sildenafil citrate sample. 
 
HPAEC-PAD Analysis of the isolated coat of a suspect counterfeit product ‘Herbal 
Sildenafil Citrate’. 
 
For the counterfeit product, the HPAEC trace of the coat has a different profile to that 
obtained with the branded and generic products: one major peak corresponding to 
galactose follows a number of small sized peaks (Figure 13). Again, a very similar 
profile was observed in the GC-MS analysis (Figure 14).  
 
 Figure 13.HPAEC-PAD chromatograph for a hydrolysed sample the film coating of a 
‘herbal sildenafil citrate sample’ with an isocratic mobile phase (NaOH 5 mM) 
 
 Figure 14 GC-MS chromatograph for a mixture of substituted alditol acetates derived 
from a sample of the film coating of a ‘herbal sildenafil citrate sample. 
 
Discussion 
 
Analysis of standards, including lactose, cellulose, croscarmellose, carboxymethyl 
cellulose and hydroxypropyl methylcellulose 
 
In order to identify the carbohydrate materials that make up the excipients in the 
sildenafil citrate tablets, analytical methods had to be chosen which were able to 
separate the analytes and which also had the appropriate sensitivity to allow 
quantification of the peaks of interest. The two methods that were chosen were 
HPAEC-PAD and GC-MS. 
 
HPAEC-PAD has many advantages over more conventional carbohydrate analysis 
techniques: it is quick to use, little sample preparation is required prior to analysis 
and it can detect very low levels of sugars. Historically, GC-MS has been the 
technique of choice for analysis of carbohydrates15 and this is because of the ability 
of the technique to resolve peaks for a large number of different sugars in a single 
analysis. However, the general procedures required to derivatise sugars before they 
can be analysed by GC-MS are lengthy and take several days to perform. 
Development of an analytical method based on HPAEC 
 
In the development of an analytical procedure for the analysis of excipients based on 
HPAEC-PAD, the first task was to establish chromatographic conditions that would 
separate simple monosaccharides and which could also separate the substituted 
monosaccharides that would be generated through the hydrolysis of the cellulose 
derivatives. A number of authors have reported the use of HPAEC-PAD16 for the 
separation of monosaccharides derived from plant and microbial sources. As a 
starting point, conditions similar to those reported by the instrument manufacturers 
were employed and involved eluting the analytes through a CarboPac PA20 column 
using sodium hydroxide as a mobile phase.  
 
Using a mobile phase composed of aqueous sodium hydroxide (6 mM), the 
hydrolysis product of lactose gave two closely eluting but base-line resolved peaks 
with retention times identical to those of glucose and galactose standards. 
Croscarmellose and carboxymethyl cellulose are prepared by a reaction which 
carboxymethylates cellulose and, depending on the degree of substitution, will have 
varying levels of carboxymethyl-substitution at C6 (4 R6= CH2CO2Na, R2 & R3 = H). 
In croscarmellose, in a subsequent condensation step, ester links are formed 
between a number of the carboxymethyl groups and a fraction of the hydroxyl groups 
on neighbouring cellulose chains. The acid hydrolysis of both polysaccharides would 
be expected to give a mixture of glucose, from unsubstituted anhydroglucoses, and 
carboxymethylated-glucoses. However, under the mildly basic conditions used to 
elute the anion column that were employed in the present study any 
carboxymethylated-glucoses would not be expected to be released from the 
CarboPac PA20 column. Indeed this was observed, when the analysis was applied to 
croscarmellose and carboxymethyl cellulose only a single peak was observed which 
had a retention time the same as that of glucose. 
When the hydrolysed hydroxypropyl methylcellulose (HPMC) was analysed a large 
number of peaks were observed on the chromatogram. HPMC is formed by two 
successive alkylations of cellulose: in the first propylene oxide is used to add 
hydroxypropyl groups to a proportion of the C6, C3 & C2 positions of the cellulose 
backbone; in the second a fraction of the remaining free hydroxyl groups i.e. at C6, 
C3, C2 and the newly added hydroxypropyl groups are methylated. The overall 
process can generate a large number of different substitution patterns for the 
anhydroglucose units (4, R2, R3, R6 = H, Me, HOPr or MeOPr). Due to steric 
constraints and because of the heterogeneous nature of the alkylation reactions, not 
all substitution patterns will be observed and some patterns will be favoured over 
others. The variability in the substitution patterns of HPMC which are generated 
during its manufacture makes this polymer an ideal candidate for use in identifying 
the origin of a tablet formulation containing HPMC. 
When the HPMC standards were analysed by HPAEC-PAD using aqueous sodium 
hydroxide as an eluent, a set of overlapping peaks was observed. Inspection of the 
chromatogram showed that six large peaks were visible (Figure 5) and a number of 
smaller peaks were also present. Given that a large number of differently substituted 
monosaccharides were expected, the observation of a relatively small number of 
peaks was surprising. At first it was thought that groups or sets of analytes containing 
the same number or types of substituents were co-eluting and attempts were made 
to increase the retention times of peaks in order to try and resolve analytes with 
similar retention times. A number of attempts were made to improve the resolution of 
the substituted monosaccharides by varying the pH of the mobile phase (4 mM-10 
mM). Unfortunately, whilst increased retention times were observed at lower sodium 
hydroxide concentrations, the resolution between peaks did not change. 
The use of aqueous sodium hydroxide as the eluent, at low milimolar concentrations, 
produces a mobile phase with a pH in the range of 12-13. At such high pHs, 
monosaccharides are ionized to varying degrees and they can be separated by anion 
exchange17. The order of elution for monosaccharides is dependent on the 
relationship between the pKa of the analyte and the pH of the eluent. The higher the 
pKa of a given analyte the earlier it will elute from the column and vice versa. 
Glucose has a pKa value of 12.28 whilst galactose has a pKa value of 12.39 and 
therefore galactose should elute before glucose and this was observed. This 
relationship between time of elution from the column and the pKa can be explained 
as a function of monosaccharide structure and the amount of hydroxyl (OH) groups 
on each structure. Generally speaking, the more acidic a molecule is the more 
hydroxyl groups it will contain and these more acidic sugars will bond tighter to the 
column than sugars that are less acidic20. This suggests that replacement of the 
hydroxyl groups with ether linkages should reduce the acidity and increase the pKa 
of the monosaccharides. However, the amount of hydroxyl groups is not the only 
reason a sugar is acidic, some hydroxyl groups provide more acidity due to their 
position on the carbon back-bone. Bruggink18 revealed that the hydroxyl group linked 
to the number one position on the pyranose ring had the biggest impact on a 
monosaccharide’s acidity. Thus, the loss of this hydroxyl group would reduce the 
elution time more so than the loss of any other hydroxyl group. The substituted 
monosaccharides generated from HPMC will all possess a hydroxyl-group at C1 and 
C4 due to the presence of the (1-4)-glycosidic linkage in cellulose, however, they will 
have varying levels of alkylation at C2, C3 and C6. The presence of the electron 
releasing alkyl groups should destabilise anion formation at C1 and consequently 
increase the pKa of the monosaccharides. This is confirmed by the elution of the 
substituted-monosaccharides of HPMC before the parent monosaccharide glucose.  
When the samples were analysed using GC-MS the chromatograms showed well 
resolved peaks. For the HPMC standard seven peaks having a peak area on the 
chromatograph representing more than 10% of that of the total were observed 
(Figure 6). As was the case in the HPAEC system, the acetylated alditols derived 
from the substituted monosaccharides eluted in advance of those generated from the 
free monosaccharides. In the GC-MS traces there is little evidence for overlapping 
peaks and this suggests that the only a specific sub-set of the substituted 
monosaccharides are present. The major advantage of the GC-MS system is that 
through the acquisition of mass spectral data the extent of methyl, hydroxypropyl and 
methoxypropyl-substitution of the different analytes could be determined. From 
inspection of the mass spectra (data not shown) it was clear that whilst the major 
peaks contained methyl-substitution there was little evidence for the presence of 
either hydroxypropyl or methoxypropyl substituents. The failure to observe the 
hydroxypropyl and methoxypropyl-substitution in the GC-MS (and more than likely 
also in the HPAEC-studies) suggests that hydrolysis of the glycosyl propyl ether link 
is occurring during monomer analysis. In order to confirm that the major peaks were 
methylated-glucoses a sample of methylcyclodextrin was hydrolysed and analysed 
by HPAEC and the acetylated alditols by GC-MS (data not shown). The retention 
times of the peaks from the HPAEC and GC were very similar and the mass spectra 
were identical to those observed for HPMC, only the ratios of the different peaks 
were different. 
Whilst our failure to observe the complete range of different substitution patterns 
reduces the amount of information available, it does have the advantage of greatly 
simplifying the chromatograms that are produced. 
Analysis of sildenafil citrate tablets 
 
Analysis of the combined tablet from the generic sildenafil citrate formulations using 
HPAEC-PAD and GC-MS  
 
The information leaflet supplied with the generic sildenafil citrate tablet identified 
cellulose, lactose and croscarmellose as the carbohydrate based excipients that 
were added in the tablet core and that HPMC was present in the film coating. 
Combined analysis of both the coat and core identified galactose and glucose and as 
such the analysis only provided information about the excipients in the tablet core. It 
is clear that the core components, cellulose, lactose and croscarmellose hydrolyse to 
give glucose and galactose, which are dominant signals in both the HPAEC-PAD and 
the GC-MS traces. The relatively small amount of HPMC from the film-coat was not 
visible.  
 
HPAEC-PAD & GC-MS analysis of the film-coat of sildenafil citrate tablets from a 
generic manufacturer and the branded product from Pfizer.  
 
As it was suspected that HPMC would provide the most information about the origin 
of different tablets, it was decided to remove the film coating from the tablets and to 
analyse these separately. Film coats were carefully removed using a scalpel taking 
care to avoid contamination of the film by core material. When the hydrolysis 
products derived from the film were analysed by HPAEC both the generic product 
and the branded product gave distinctive chromatographs. The excipients used by 
manufacturers in the film coating vary: the generic manufacturer lists HPMC as the 
only carbohydrate based excipient present in the coat whereas Pfizer lists both 
lactose and HPMC as being present. When the HPAEC and GC-MS traces were 
analysed there was evidence for both galactose and glucose in both samples (7.2 
and 8.3 min peaks in the HPAEC and 13.2 and 12.9 in the GC Figs 7-10). It was not 
clear why galactose, which can only be derived from lactose, was visible in the film-
coating from the generic product. The ratio of glucose to galactose was very similar 
in the two samples and this was to be expected if these were primarily derived from 
lactose.  
 
The chromatography traces also provided strong evidence for the presence of 
substituted monosaccharides which were more than likely derived from the HPMC. 
The number of peaks (excluding glucose and galactose) was the same for each 
sample; the only difference was in the relative abundance of signals within each 
sample and the difference in relative abundance of particular signals between the 
different samples.  
 
HPAEC-PAD Analysis of the isolated coat of a suspect counterfeit product ‘Herbal 
Sildenafil Citrate’  
 
The HPAEC-chromatograph obtained for the analytes released during hydrolysis of 
the film-coat from the herbal sildenafil citrate tablet contained one large peak which 
co-eluted with galactose. A number of smaller peaks which corresponded to those 
expected for the substituted monosaccharides derived from HPMC were visible in 
front of the galactose peaks. Inspection of the chromatogram clearly demonstrates 
that the ‘Herbal Sildenafil’ has been manufactured using coating technology 
employing HPMC. It is clear that the different HPAEC profiles of the ‘herbal’ product, 
the branded product and the generic products suggest that the material has been 
manufactured and formulated independently and is not a misplaced product that has 
been diverted from a legitimate manufacturing operation. It is worth noting that NMR 
analysis was used to determine that this product, which was labelled as ‘Herbal 
Viagra’, contained sildenafil citrate as its API, a 1H NMR spectrum of a chloroform 
extract of the tablet core confirmed the identity of the API. 
 
Conclusion 
To summarise, the aim of this work was to investigate the differences and similarities 
of excipients within pharmaceutical products and to create a method by which 
counterfeit products could be detected. The success of the project has largely been 
the development of a technique employing HPAEC for the development of a 
‘fingerprint’ for formulations containing HPMC as excipients. 
In future work, it is proposed that a library should be developed of HPMC ‘finger-
prints’ for a wide range of commercial excipients and that the library could then be 
used to routinely test the integrity of supply chains of legitimate branded 
pharmaceutical and generic products . 
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